The company has gained an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma.
The terms of the agreement have not been disclosed.
The company will utilize the property in the development and commercialization of ICT-140, a multivalent, dendritic cell-based vaccine for the treatment of ovarian cancer, one of multiple tumor types in which mesothelin is over-expressed.
ImmunoCellular president and CEO Manish Singh said the licensing agreement for mesothelin technology will allow the company to ensure that it has the critical components for a successful vaccine.
"We expect to file an Investigative New Drug application for the vaccine in the fourth quarter of this year," Singh added.